^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GD2-CART01

    i
    Associations

    News

    Trials
    Company:
    Bambino Gesu Hospital
    Drug class:
    GD2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk And/or Relapsed/refractory Neuroblastoma or Other GD2-positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Trial primary completion date: Dec 2024 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    GD2-CART01
    over1year
    GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply. (PubMed, N Engl J Med)
    No abstract available
    Journal
    |
    GD2-CART01